6.37
-0.03 (-0.47%)
| Previous Close | 6.40 |
| Open | 6.38 |
| Volume | 2,279 |
| Avg. Volume (3M) | 79,478 |
| Market Cap | 545,150,272 |
| Price / Sales | 2.67 |
| Price / Book | 2.87 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Profit Margin | -7.22% |
| Operating Margin (TTM) | -38.61% |
| Diluted EPS (TTM) | -0.180 |
| Quarterly Revenue Growth (YOY) | 26.40% |
| Total Debt/Equity (MRQ) | 119.34% |
| Current Ratio (MRQ) | 2.61 |
| Operating Cash Flow (TTM) | -67.22 M |
| Levered Free Cash Flow (TTM) | -83.02 M |
| Return on Assets (TTM) | -10.03% |
| Return on Equity (TTM) | -7.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Valneva SE | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 0.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| General American Investors Co Inc | 31 Dec 2024 | 354,361 |
| Ironwood Investment Management Llc | 31 Dec 2024 | 25,022 |
| Vsm Wealth Advisory, Llc | 31 Dec 2024 | 1,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (HC Wainwright & Co., 166.88%) | Buy |
| Median | 15.50 (143.33%) | |
| Low | 14.00 (Guggenheim, 119.78%) | Buy |
| Average | 15.50 (143.33%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 08 May 2025 | 14.00 (119.78%) | Buy | 6.38 |
| 24 Mar 2025 | 15.00 (135.48%) | Buy | 7.43 | |
| HC Wainwright & Co. | 15 Apr 2025 | 17.00 (166.88%) | Buy | 7.05 |
| 09 Apr 2025 | 17.00 (166.88%) | Buy | 6.77 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |